We performed a single-arm phase II clinical trial to evaluate 1- and 2-year relapse rates in 41 cases following radical treatment of HCC using GPC3 peptide vaccine as adjuvant therapy (Table 1) (31). Here, GPC3 is linked to hepatocellular carcinoma.